Literature DB >> 3506820

Use of biological fluids for the rapid diagnosis of potentially lethal inherited disorders of human purine and pyrimidine metabolism.

G S Morris1, H A Simmonds, P M Davies.   

Abstract

Inherited purine and pyrimidine disorders may be associated with serious, sometimes life-threatening consequences. Early and accurate diagnosis is essential. Difficulties encountered when using existing high pressure liquid chromatographic (HPLC) methods led to the development of an improved method based on prior fractionation of urine. The advantages are as follows. 1. Production of fingerprints demonstrating altered urinary excretion patterns characteristic of any one of ten different disorders, in 30 minutes. 2. Positive identification and quantification by comparison with established methods (using conventional chromatography, electrophoresis and UV spectrophotometry) in addition to specific retention times and characteristic UV absorbance ratios at two separate wavelengths (245 and 280 nm) by HPLC. 3. Direct analysis of all the purines and pyrimidines normally found in human body fluids as well as identification of abnormal compounds. 4. Short time between successive analyses while maintaining excellent resolution between compounds of interest and column longevity. 5. Improved separation of the different adenine-based compounds encountered in some disorders, plus demonstration of potential interference by dietary or drug metabolites. 6. Applicability to the monitoring of therapy involving a variety of different purine and pyrimidine analogues. Particular attention should be paid to sample preparation. Plasma profiles will confirm the diagnosis in some, but not all, of these disorders.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3506820     DOI: 10.1002/bmc.1130010305

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  7 in total

1.  Urinary uracil concentrations are a useful guide to genetic disorders associated with neurological deficits and abnormal pyrimidine metabolism.

Authors:  P M Davies; L D Fairbanks; J A Duley; H A Simmonds
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

2.  Characterization of LC-MS based urine metabolomics in healthy children and adults.

Authors:  Xiaoyan Liu; Xiaoyi Tian; Shi Qinghong; Haidan Sun; Li Jing; Xiaoyue Tang; Zhengguang Guo; Ying Liu; Yan Wang; Jie Ma; Ren Na; Chengyan He; Wenqi Song; Wei Sun
Journal:  PeerJ       Date:  2022-06-22       Impact factor: 3.061

3.  Vitreous humour and cerebrospinal fluid hypoxanthine concentration as a marker of pre-mortem hypoxia in SIDS.

Authors:  K H Carpenter; J R Bonham; E Worthy; S Variend
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

4.  Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency.

Authors:  G Morgan; R J Levinsky; K Hugh-Jones; L D Fairbanks; G S Morris; H A Simmonds
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

5.  Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis.

Authors:  Dino Bullinger; Richard Fux; Graeme Nicholson; Stefan Plontke; Claus Belka; Stefan Laufer; Christoph H Gleiter; Bernd Kammerer
Journal:  J Am Soc Mass Spectrom       Date:  2008-06-28       Impact factor: 3.109

6.  Exometabolom analysis of breast cancer cell lines: Metabolic signature.

Authors:  Lucas Willmann; Thalia Erbes; Sebastian Halbach; Tilman Brummer; Markus Jäger; Marc Hirschfeld; Tanja Fehm; Hans Neubauer; Elmar Stickeler; Bernd Kammerer
Journal:  Sci Rep       Date:  2015-08-21       Impact factor: 4.379

7.  Behavioural and molecular endophenotypes in psychotic disorders reveal heritable abnormalities in glutamatergic neurotransmission.

Authors:  L Scoriels; R M Salek; E Goodby; D Grainger; A M Dean; J A West; J L Griffin; J Suckling; P J Nathan; B R Lennox; G K Murray; E T Bullmore; P B Jones
Journal:  Transl Psychiatry       Date:  2015-03-31       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.